Cytomegalovirus Infections in Patients Treated With Immune Checkpoint Inhibitors for Solid Malignancies.
cytomegalovirus
immune-checkpoint inhibitors
immune-related adverse events
immune-related colitis
review
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
06
09
2022
accepted:
26
03
2023
medline:
18
4
2023
entrez:
17
4
2023
pubmed:
18
4
2023
Statut:
epublish
Résumé
Cytomegalovirus (CMV) infection/disease has been repeatedly reported in patients treated with immune-checkpoint inhibitors (ICIs) and most commonly involves patients with relapsed/refractory (R/R) immune-related adverse events (irAEs). In the current study, we present a patient with melanoma who developed CMV gastritis during treatment with pembrolizumab in the absence of irAEs and without previous or current immunosuppression. Moreover, we review the literature regarding CMV infection/disease in patients treated with ICIs for solid malignancies. We present the currently available data on the pathogenesis, clinical characteristics, endoscopic findings, and histologic features and highlight the potential differences among cases complicating R/R irAEs versus those occurring in patients who are immunosuppression naive. Finally, we discuss the currently available data regarding potential useful diagnostic tools as well as the management of these patients.
Identifiants
pubmed: 37065986
doi: 10.1093/ofid/ofad164
pii: ofad164
pmc: PMC10099470
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
ofad164Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. PD reports personal fees from Novartis, Amgen, Janssen, and Roche. JH reports the following: financial compensation (to the institute) for advisory roles by Achilles Therapeutics, BioNTech, BMS, GSK, Immunocore, Iovance Bio, Instill Bio, Ipsen, MSD, Molecular Partners, Novartis, Pfizer, PokeAcel, Roche, Sanofi, and T-Knife; personal fees for advisory roles in Neogene Therapeutics, Scenic, grant support (all paid to the institute) by Amgen, Asher Bio, BioNTech, BMS, MSD, Novartis; and owner of stock options in Neogene Therapeutics. HG reports grants and personal fees from BMS and MSD and personal fees from Novartis, Pierre Fabre, Amgen, Sanofi/Regeneron, and Pfizer. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
J Thorac Oncol. 2020 Jan;15(1):e15-e20
pubmed: 31864555
Am J Clin Pathol. 2017 Jan 01;147(1):96-104
pubmed: 28007703
Clin Infect Dis. 2016 Dec 1;63(11):1490-1493
pubmed: 27501841
Clin Infect Dis. 2017 Jan 1;64(1):87-91
pubmed: 27682069
Case Rep Gastroenterol. 2020 Feb 25;14(1):103-109
pubmed: 32231510
Transplantation. 1994 Sep 27;58(6):675-80
pubmed: 7940686
Transpl Infect Dis. 2021 Jun;23(3):e13531
pubmed: 33249726
Mol Clin Oncol. 2021 Apr;14(4):65
pubmed: 33680456
Eur J Cancer. 2017 Nov;86:248-256
pubmed: 29055840
Front Cell Infect Microbiol. 2020 Mar 31;10:130
pubmed: 32296651
Virchows Arch. 2015 May;466(5):533-9
pubmed: 25701481
World J Gastroenterol. 2015 Feb 14;21(6):1915-26
pubmed: 25684960
J Immunother. 2015 Jun;38(5):212-5
pubmed: 25962110
Infect Dis Ther. 2018 Mar;7(1):1-16
pubmed: 29204910
Dig Liver Dis. 2004 Dec;36(12):818-20
pubmed: 15646428
Nat Commun. 2020 Jul 30;11(1):3801
pubmed: 32732879
Intern Med J. 2022 Oct;52(10):1759-1767
pubmed: 34448333
Inflamm Bowel Dis. 2004 May;10(3):245-50
pubmed: 15290919
Br J Haematol. 2013 Aug;162(3):313-25
pubmed: 23691926
Pediatr Gastroenterol Hepatol Nutr. 2013 Jun;16(2):123-6
pubmed: 24010116
BMJ Case Rep. 2020 May 19;13(5):
pubmed: 32434876
Nat Med. 2019 Aug;25(8):1243-1250
pubmed: 31332390
Am J Gastroenterol. 2006 Dec;101(12):2857-65
pubmed: 17026558
Eur J Cancer. 2019 Mar;109:172-174
pubmed: 30731278
J Clin Oncol. 2021 Dec 20;39(36):4073-4126
pubmed: 34724392
Front Immunol. 2021 Oct 29;12:768957
pubmed: 34777387
Rev Med Virol. 2010 Jul;20(4):202-13
pubmed: 20564615
Ulcers. 2011 Jan 1;2011:
pubmed: 21731826
Nat Rev Microbiol. 2021 Dec;19(12):759-773
pubmed: 34168328
Cureus. 2020 Jan 15;12(1):e6670
pubmed: 32104613
Inflamm Bowel Dis. 2016 Dec;22(12):2966-2976
pubmed: 27763950
Clin Colorectal Cancer. 2020 Dec;19(4):e183-e188
pubmed: 32703755
J Clin Gastroenterol. 2012 Jan;46(1):51-6
pubmed: 21552140
Transplantation. 1992 Nov;54(5):887-96
pubmed: 1332226
ACG Case Rep J. 2022 Feb 23;9(2):e00747
pubmed: 35224125
Gastroenterology Res. 2018 Oct;11(5):383-387
pubmed: 30344812
Oncoimmunology. 2016 Feb 18;5(6):e1128611
pubmed: 27471608
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Aliment Pharmacol Ther. 2014 Apr;39(7):712-20
pubmed: 24506221
Mol Clin Oncol. 2021 Jun;14(6):120
pubmed: 33903826
Clin Gastroenterol Hepatol. 2015 Jan;13(1):131-7; quiz e7
pubmed: 24993369
Curr Oncol. 2020 Aug;27(4):e436-e439
pubmed: 32905211